While leukemia stem cells (LCSs) are generally CD34+/CD38−, the abnormal HSC populations in CML have extremely heterogeneous and unstable cell surface antigens expression, and vary greatly in terms of their leukemogenic capacity [8,17,21,30,31]. Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.